Literature DB >> 12742271

Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results.

Marc W Münter1, Christoph Thilmann, Holger Hof, Bernd Didinger, Bernhard Rhein, Simeon Nill, Wolfgang Schlegel, Michael Wannenmacher, Jürgen Debus.   

Abstract

PURPOSE/
OBJECTIVE: The aim of this analysis is to evaluate the feasibility of inverse treatment planning and intensity modulated radiation therapy (IMRT) for head and neck cancer in daily clinical routine. A step and shoot IMRT approach was developed which allows the treatment of large target volumes without the need to use a split beam technique. By using the IMRT approach better protection of different organs at risk in the head and neck region may be achieved and an escalation of the dose in the tumor should be possible. We evaluated the feasibility of the treatment technique and the patient tolerance to the treatment. First clinical results are reported.
MATERIALS AND METHODS: Between 1999 and 2002, 48 patients with a carcinoma of the head and neck region were treated with curative intention. All patients were treated in a patient-specific Scotch-Cast mask. Patients who required treatment of the lymph node levels I-VI, were additionally positioned by a vacuum pillow in order to immobilize the upper part of the thorax. For inverse treatment planning, the software module KonRad was used which was integrated into the VIRTUOS planning system. Each treatment plan was verified using quantitative film dosimetry in a head and neck phantom. The step and shoot IMRT technique with a multileaf collimator integrated in a Primus (Siemens) accelerator was used for treatment. For all target volumes the whole target including the lymph nodes were covered completely by the IMRT treatment.
RESULTS: The mean total dose for the target volumes of macroscopic disease ranged between 63.0 and 64.1 Gy. The mean total dose of microscopic disease ranged between 55.2 and 60.1 Gy. The mean percentage of planning target volume receiving <90% of the prescribed dose ranged between 3.0 and 11.5%. For the treatment, the median number of beams was seven (range: five to nine). The time to deliver the treatment ranged between 9 and 18 min. The results of the verification revealed a mean deviation between measured and calculated absolute doses for the 48 patients of 0.1+/-1.4%. Including the phantom verification the IMRT treatment of the patients could be started approximately after five working days. The treatment was well tolerated by all patients. The 2-year actuarial overall survival was 92% and the 2-year actuarial local control rate was 93%. According to the Radiation Therapy Oncology Group (RTOG), no higher acute toxicity than Grade 3 was seen. Observation of the late effects revealed only one transient Grade 4 toxicity of the bone and only four patients had a xerostomia higher than Grade 1.
CONCLUSION: The use of an inversely-planned and intensity-modulated step and shoot approach is feasible in clinical routine for head and neck tumors. Treatment could be applied as planned and no increased toxicity was found. Compared to other IMRT approaches for the head and neck region the used technique allows the treatment of the primary tumor and the lymph nodes level I-VI with only one intensity modulated treatment volume. The presented technique avoids to match conventional radiotherapy fields and IMRT fields, and therefore, reduce the risk of overdosage or underdosage at the matching line. Compared to conventional treatment techniques IMRT shows advantages in tumor dose and dose at the organs at risk.

Entities:  

Mesh:

Year:  2003        PMID: 12742271     DOI: 10.1016/s0167-8140(03)00021-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  [Technical and methodical developments of radiation oncology from a physician's point of view].

Authors:  N Willich
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

Review 2.  [What is the impact of new radiotherapy techniques?].

Authors:  F Sterzing; M W Münter; A D Jensen; E M Stoiber; P Huber; K K Herfarth; J Debus
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

3.  IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.

Authors:  Felix Zwicker; Falk Roeder; Christian Thieke; Carmen Timke; Marc W Münter; Peter E Huber; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

Review 4.  Intensity modulated radiotherapy (IMRT) in benign giant cell tumors--a single institution case series and a short review of the literature.

Authors:  Falk Roeder; Carmen Timke; Felix Zwicker; Christian Thieke; Marc Bischof; Jürgen Debus; Peter E Huber
Journal:  Radiat Oncol       Date:  2010-02-26       Impact factor: 3.481

5.  Long-term local control of recurrent adenoid cystic carcinoma in the parotid gland with radiotherapy and intraarterial infusion chemotherapy.

Authors:  Koutarou Terashima; Yoshiyuki Shioyama; Katsumasa Nakamura; Saiji Ohga; Satoshi Nomoto; Toshihiro Yamaguchi; Takashi Toba; Tadamasa Yoshitake; Hidetake Yabuuchi; Torahiko Nakashima; Hiromi Terashima; Hiroshi Honda
Journal:  Radiat Med       Date:  2006-05

6.  Hemangiopericytomas of the spine: case report and review of the literature.

Authors:  Chad D Cole; Meic H Schmidt
Journal:  Rare Tumors       Date:  2009-12-28

7.  Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer.

Authors:  Falk Roeder; Felix Zwicker; Ladan Saleh-Ebrahimi; Carmen Timke; Christian Thieke; Marc Bischof; Juergen Debus; Peter E Huber
Journal:  Radiat Oncol       Date:  2011-03-01       Impact factor: 3.481

8.  Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.

Authors:  Stephanie E Combs; Steffen Heeger; Renate Haselmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2006-05-18       Impact factor: 4.430

9.  The emerging role of IG-IMRT for palliative radiotherapy: a single-institution experience.

Authors:  R Samant; L Gerig; L Montgomery; R Macrae; G Fox; B Nyiri; K Carty; M Macpherson
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

10.  Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis.

Authors:  Ladan Saleh-Ebrahimi; Felix Zwicker; Marc W Muenter; Marc Bischof; Katja Lindel; Juergen Debus; Peter E Huber; Falk Roeder
Journal:  Radiat Oncol       Date:  2013-01-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.